Vemurafenib was, on the other hand, quantitated successfully in the matched CSF and plasma samples of patients treated with the drug in a dose of 960 mg, given twice daily, for brain metastatic BRAF-V600 mutated melanoma. This evidence concerns the gene BRAF and melanoma.